Enabling personalized cancer medicine through analysis of gene-expression patterns
Top Cited Papers
- 2 April 2008
- journal article
- review article
- Published by Springer Nature in Nature
- Vol. 452 (7187) , 564-570
- https://doi.org/10.1038/nature06915
Abstract
Therapies for patients with cancer have changed gradually over the past decade, moving away from the administration of broadly acting cytotoxic drugs towards the use of more-specific therapies that are targeted to each tumour. To facilitate this shift, tests need to be developed to identify those individuals who require therapy and those who are most likely to benefit from certain therapies. In particular, tests that predict the clinical outcome for patients on the basis of the genes expressed by their tumours are likely to increasingly affect patient management, heralding a new era of personalized medicine.Keywords
This publication has 49 references indexed in Scilit:
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006
- Genomic signatures to guide the use of chemotherapeuticsNature Medicine, 2006
- The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurementsNature Biotechnology, 2006
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Computational analysis of microarray dataNature Reviews Genetics, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998